TempraMed Secures New South Korea Patent for VIVI Box Medication Storage System

TempraMed Technologies has strengthened its global intellectual property portfolio with a newly granted patent in South Korea. The patent protects its VIVI Box technology, designed to safely store temperature-sensitive medicines at home and on the move.

This milestone reinforces TempraMed’s push to redefine how patients manage biologics and specialty drugs outside traditional cold chains.

What the New Patent Covers?

The South Korea patent safeguards TempraMed’s proprietary thermal-insulation system and smart monitoring architecture behind VIVI Box.

Key protections include:

• Passive thermal insulation that works without batteries or external power
• Smart temperature stabilization within domestic refrigerators
• Adaptability across multiple drug formats and categories

This expands the company’s ability to support everything from chronic injectables to advanced biologics.

Why VIVI Box Matters?

VIVI Box is a consumer-focused medical storage system built for real-world patient use. It is engineered to:

• Prevent accidental freezing inside household refrigerators
• Maintain a stable 8°C environment for up to 24 hours without power
• Protect medicines during travel, transport, and power outages

The system bridges the gap between strict pharmacy cold-chain standards and everyday patient behaviour.

Built for Fast-Growing Drug Categories

VIVI Box is designed to support:

• Insulin and diabetes therapies
• GLP-1 treatments
• Biologics and specialty medicines

By offering a reusable and reliable storage solution, TempraMed helps reduce medication waste and protect treatment efficacy.

Smart Features That Set It Apart

Beyond temperature control, the patented technology includes:

• Continuous protection during power interruptions
• Portable, all-day cold storage for travel
• Smart content tracking with cloud-based data integration

This positions VIVI Box at the intersection of home health, smart appliances, and medical IoT.

Part of a Bigger Commercial Strategy

According to CEO Ron Nagar, the patent marks a key step in TempraMed’s long-term vision. The company aims to move beyond single-injection protection into scalable, multi-medication storage platforms. These systems are central to its global commercialization plans.

Expanding Global Reach

The South Korea patent follows recent distribution agreements across:

• Israel
• Turkey
• Major European markets

Partners include Guri A.A.O, Dolfin Saglik, and Salomo Executive, expanding access through pharmacies and healthcare networks.

The Bigger Picture

TempraMed Technologies is building a global platform for temperature-stable medication management. With FDA-registered products like VIVI Cap and VIVI Epi, and new systems like VIVI Box, the company is raising the standard for medication storage.

As biologics and GLP-1 therapies grow worldwide, safe and compliant storage is no longer optional. TempraMed is positioning itself to lead that shift.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!